Skip to main content


Table 1 MAPK7 gene amplification prevalence in Chinese NSCLC and sqEC

From: Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma

Tumor types MAPK7 AMP prevalence
NSCLC 4 % (3/74) (enriched to 3/49 in squamous cell lung)
sqEC 2 % (2/95)